By Lina carolina 
Researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, have unveiled a significant breakthrough in the fight against bowel cancer, identifying the protein CD74 as a potential biomarker capable of predicting which patients are most likely to respond to life-saving immunotherapy treatments. This discovery holds the promise of expanding eligibility for immunotherapy to hundreds of patients who were previously considered unsuitable for this advanced form of cancer therapy, potentially revolutionizing treatment paradigms for a substantial portion of the bowel cancer patient population.
Bowel cancer, a formidable adversary, stands as the fourth most prevalent cancer and the second leading cause of cancer-related mortality in the United Kingdom. The disease’s complexity is underscored by its classification into two primary subtypes: the deficient subtype, characterized by deficiencies in DNA repair protein machinery, and the proficient subtype, where this critical repair mechanism remains intact. While cancer immunotherapies, designed to harness and amplify the body’s own immune system to combat malignant cells, have dramatically altered the treatment landscape for the deficient subtype, their efficacy remains limited. Approximately half of patients with the deficient subtype experience benefits, while the proficient subtype, which constitutes a staggering 90% of all bowel cancer cases, currently remains largely ineligible for immunotherapy.
The groundbreaking study, published today in the esteemed journal Cancer Cell, delves into the intricate reasons behind immunotherapy’s variable success rates and explores avenues to broaden its therapeutic reach. The research team’s meticulous investigation pinpointed the expression levels of CD74, a protein previously less understood in this context, as a critical determinant of immunotherapy response, irrespective of the underlying cancer subtype. This finding challenges existing assumptions and opens new avenues for personalized treatment strategies.
The Crucial Role of the Tumour Microenvironment in Immunotherapy Efficacy
Central to the researchers’ investigation was an in-depth examination of the immune cells residing within and surrounding various tumour types. The composition and activity of this "tumour microenvironment" have long been recognized as pivotal factors influencing a patient’s response to immunotherapy. By analyzing samples from both deficient and proficient subtypes, and comparing individuals who responded to immunotherapy with those who did not, the team sought to unravel the immunological signatures associated with successful treatment.
Their analysis revealed a critical triad of immune cell types essential for a robust anti-tumour response to immunotherapy: cytotoxic T cells, often referred to as "fighter cells," Natural Killer (NK) cells, which also play a direct role in eliminating infected or cancerous cells, and macrophages. Macrophages, in this context, act as crucial intermediaries, presenting antigens – molecular flags – on their surfaces that signal the presence of a threat to other immune cells, thereby initiating an orchestrated immune attack.
When these three immune cell populations were present in close proximity to cancer cells, a significant cascade of molecular signaling was observed. T cells and NK cells released potent molecules known as interferons. These interferons, in turn, triggered a signaling pathway within macrophages and the tumour cells themselves. This intricate communication network was found to be significantly more active in tumours of the deficient subtype that responded positively to immunotherapy. However, a surprising revelation emerged: a subset of patients with the proficient subtype also exhibited a comparable level of this crucial signaling, suggesting that their immune systems might already be primed for an effective response to immunotherapy, even without the characteristic DNA repair deficiencies.
CD74: A Novel Biomarker for Predicting Immunotherapy Success
Motivated by the observation of enhanced immune signaling in responsive tumours, the research team sought a more direct and clinically applicable indicator to assess the immune system’s readiness for immunotherapy. Their pursuit led them to explore the protein CD74. Employing a cutting-edge technology called spatial transcriptomics, which allows for the analysis of gene expression within specific spatial locations of a tissue sample, they observed a compelling correlation.
Spatial transcriptomics revealed that T cells, when stimulated, were prompting nearby macrophages and tumour cells to produce CD74. Crucially, tumours that were actively responding to immunotherapy drugs consistently exhibited higher levels of CD74 expression. This finding provided a tangible molecular link between a favourable immune environment and the presence of CD74.
To rigorously validate the potential of CD74 as a clinical biomarker, the researchers expanded their study to include samples from several international clinical trials. These trials specifically focused on patients with the proficient subtype of bowel cancer who were receiving immunotherapy. The results were highly encouraging: individuals who demonstrated a positive response to immunotherapy consistently showed significantly higher levels of CD74 compared to those who did not respond. This independent validation across multiple trial cohorts solidified CD74’s role as a reliable predictor of immunotherapy response, irrespective of the patient’s tumour subtype.
The implications of this finding are profound. It suggests that measuring CD74 levels could become a routine diagnostic tool, enabling clinicians to accurately identify patients who are most likely to benefit from immunotherapy. For individuals with the proficient subtype, who currently represent a large, underserved population, this could mean access to a treatment that was previously out of reach. Furthermore, for patients with the deficient subtype who might not respond to immunotherapy, identifying this through CD74 testing could prevent them from undergoing potentially ineffective and burdensome treatments, thereby avoiding unnecessary side effects and associated healthcare costs.
Expert Perspectives and Future Directions
Francesca Ciccarelli, Principal Group Leader of the Cancer Systems Biology Laboratory at the Crick and Professor of Cancer Genomics at Queen Mary University of London’s Barts Cancer Institute, articulated the transformative potential of this research. "Immunotherapy drugs can be hugely successful for people with bowel cancer," she stated, "but currently the majority of patients can’t be prescribed these drugs and, even when patients are eligible, we don’t know upfront who will respond." She further emphasized, "Our work suggests that testing for CD74 levels — which signal that the immune system is ‘just right’ to fight the tumour — could widen access to immunotherapy. This could revolutionise treatment for a sizeable fraction of people with the proficient bowel cancer subtype, which is a large number of patients across the UK in real terms. It could also be used to identify people with the deficient subtype who won’t respond, saving them from experiencing side effects unnecessarily."
Kalum Clayton, a former postdoc at the Crick and joint first author of the study alongside Pietro Andrei and Amelia Acha, highlighted the power of advanced research methodologies. "Our work shows how state-of-the-art technologies coupled with computational analysis can address important clinical questions," he commented. "As an early career research scientist, seeing the potential of our work to provide benefit to patients and their families is greatly rewarding."
The research team is not resting on their laurels. They are actively collaborating with Cancer Research Horizons, the commercialization arm of Cancer Research UK, to translate these promising findings into a clinically viable diagnostic test. Concurrently, further research is planned to elucidate the precise mechanisms by which macrophages and tumour cells overexpress CD74, and to investigate whether this critical marker is also relevant in the context of other cancer types. This ongoing commitment to research and development underscores the translational nature of this discovery.
Anna Kinsella, Science Engagement Manager at Cancer Research UK, lauded the study’s contribution to the broader fight against cancer. "Immunotherapy treatments, such as immune checkpoint inhibitors, use the power of the immune system to fight cancer," she explained. "Whilst these treatments benefit some people with bowel cancer, they aren’t effective for everyone." She added, "Although further research is needed, studies like this — diving deep into the biology of tumours — help researchers find ways to predict when immunotherapy is likely to work. In the future, this could help clinicians tailor treatment and allow more people with bowel cancer to benefit from immunotherapy." Kinsella concluded by reinforcing Cancer Research UK’s dedication to discovery research, stating, "Understanding the biology of cancer is vital to unlocking better ways to prevent, detect and treat it, so that people can live longer, better lives free from the fear of cancer. That’s why at Cancer Research UK, discovery research is at the heart of everything we do."
The collaborative spirit of this research is further evidenced by the involvement of esteemed institutions including UCL, the University of Pisa, King’s College London, the Sarah Cannon Research Institute, and the Veneto Institute of Oncology, underscoring the global effort to advance cancer care.
Broader Impact and Implications for Bowel Cancer Treatment
The identification of CD74 as a predictor of immunotherapy response carries significant implications for the future management of bowel cancer. Historically, treatment decisions for bowel cancer have been largely dictated by the tumour’s stage, grade, and the presence or absence of specific genetic mutations. While these factors remain crucial, the incorporation of predictive biomarkers like CD74 offers a more nuanced and personalized approach.
Timeline of Discovery and Development:
- Early Research & Hypothesis Formation: The study likely began with foundational research into the tumour microenvironment and the immunological differences between responsive and non-responsive bowel cancer cases. This phase would have involved extensive data collection and initial hypothesis generation regarding key molecular players.
- Advanced Technological Application: The integration of cutting-edge techniques like spatial transcriptomics marked a pivotal stage, enabling the detailed mapping of cellular interactions and gene expression within tumours. This allowed for the identification of novel protein candidates like CD74.
- Validation in Clinical Trials: The critical step of testing CD74’s predictive power in existing international clinical trial data provided robust evidence of its efficacy across diverse patient populations. This phase is crucial for establishing the biomarker’s reliability.
- Translation to Clinical Practice: The current stage involves collaboration with commercial entities like Cancer Research Horizons to develop a standardized, accessible diagnostic test. This process typically involves further refinement, regulatory approval, and integration into clinical workflows.
- Ongoing Research: Future research will focus on understanding the fundamental biology behind CD74’s role and exploring its applicability to other cancer types, potentially expanding its impact even further.
Supporting Data and Context:
- Prevalence of Bowel Cancer: In the UK alone, over 43,000 new cases of bowel cancer are diagnosed annually, with approximately 16,500 deaths. This highlights the substantial unmet need for more effective treatment strategies.
- Immunotherapy’s Current Reach: While immunotherapy has revolutionized care for certain cancers, its application in bowel cancer has been primarily limited to the deficient subtype, leaving the vast majority of patients with the proficient subtype with fewer advanced treatment options.
- Cost-Effectiveness: By identifying patients who are likely to respond, CD74 testing could prevent the administration of expensive immunotherapy to non-responders, leading to significant cost savings for healthcare systems and reducing the burden of unnecessary treatment on patients.
- Reduced Side Effects: Immunotherapy, while powerful, can have significant side effects. Identifying non-responders beforehand can spare patients from experiencing these adverse events, improving their quality of life during treatment.
Analysis of Implications:
The discovery of CD74 as a predictive biomarker represents a paradigm shift in how bowel cancer patients might be treated. It moves beyond a one-size-fits-all approach and embraces precision medicine, where treatment is tailored to the individual’s biological profile. This has the potential to:
- Increase Survival Rates: By enabling more patients to access effective immunotherapy, survival rates for bowel cancer could see a marked improvement.
- Enhance Patient Quality of Life: Avoiding ineffective treatments and their associated side effects will significantly improve the well-being of patients.
- Drive Further Research: The success of CD74 may spur further research into other molecular markers and immune-based strategies for different cancer subtypes.
- Global Health Impact: As the research is published and disseminated, it has the potential to influence treatment guidelines and practices worldwide, benefiting patients globally.
The collaborative effort between leading research institutions, coupled with the use of advanced scientific tools and a clear vision for clinical translation, underscores the power of scientific inquiry to address pressing healthcare challenges. The journey from laboratory discovery to widespread clinical application is often long and complex, but the findings regarding CD74 offer a beacon of hope for countless individuals affected by bowel cancer.